Clinical implications of TT virus superinfection in patients with chronic hepatitis C.
OBJECTIVE
TT virus (TTV) has been identified as a candidate agent of non-A-E hepatitis virus. We investigated superinfection of TTV in patients with chronic hepatitis C and studied the susceptibility to interferon (IFN) treatment and its association with liver disease caused by hepatitis C virus (HCV).


METHODS
TTV DNA was examined using the seminested polymerase chain reaction (PCR), and its virus level was measured by the real-time fluorometric PCR.


RESULTS
TTV DNA was detected in 20 of 102 (19.6%) patients examined. There was no significant difference in the alanine aminotransferase (ALT) level between patients with or without TTV DNA. Quantitative analysis of HCV RNA and TTV DNA revealed no correlation between virus levels in HCV/TTV-coinfected patients. Both TTV and HCV were sensitive to IFN therapy. Complete response to IFN with a sustained loss of viremia for 24 wk after completion of IFN treatment was found in 11 of 20 (55%) patients with respect to TTV DNA and in five of 20 (25%) patients with respect to HCV RNA. The mean pretreatment HCV RNA level was significantly lower in the complete-response cases than in the no-response cases, but there was no significant difference in the pretreatment TTV DNA levels between them. ALT normalization resulting from IFN therapy was not attributable to the eradication of TTV DNA but was attributable to that of HCV RNA. Superinfection by TTV did not influence the effect of IFN against HCV. No specific TTV genotype correlating with IFN sensitivity was found.


CONCLUSIONS
These results suggest that TTV infection stands independent of HCV infection, with no influence on liver injury as a result of HCV infection.
Second Department of Internal Medicine, Yamagata University School of Medicine, Iida, Japan.
H
H
Watanabe
T
T
Saito
O
O
Kawamata
L
L
Shao
M
M
Aoki
Y
Y
Terui
H
H
Mitsuhashi
T
T
Matsuo
Y
Y
Takeda
K
K
Saito
H
H
Togashi
H
H
Shinzawa
T
T
Takahashi
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use; D004266:DNA Virus Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D004267:DNA Viruses / Q000235:genetics; D004279:DNA, Viral / Q000097:blood; D005260:Female; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D015163:Superinfection
D000998:Antiviral Agents; D004279:DNA, Viral; D012367:RNA, Viral; D007372:Interferons